Sagemcom Reinvents the Home Entertainment Experience, with the Launch of Video Soundbox™, the World First Dolby Atmos Certified 4K Set-Top Box, Including an Audio Solution Designed with Bang & Olufsen
15.7.2021 12:00:00 EEST | Business Wire | Press release
The Video Soundbox is a product for service operators. It has been developed with Dolby to become the first certified Dolby Atmos video / audio hub, delivering an immersive sound for all types of contents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005017/en/
VSB Sagemcom (Photo: Business Wire)
Crafted and tuned by the world-renowned acoustic experts at Bang & Olufsen, Sagemcom Video Soundbox is equipped with a bespoke audio solution, the resulting sound is both natural and authentic, and the listening experience is as the artist originally intended it to be. With “Audio by Bang & Olufsen”, the Video Soundbox makes you feel what you’re hearing.
The great sound quality of the device is combined with its ability to access to best video and music contents, to grant the users a seamless access to a premium entertainment experience.
Thanks to optimal microphone implementation and performing noise cancellation system, the Video Soundbox offers accurate voice recognition that brings user-friendly far field voice control to access all contents:
- Premium 4K videos through linear channels and integrated streaming VOD services, such as Netflix, Amazon Prime Video and many others.
- Premium music with access to Spotify and Amazon Music, and more to come
- Integrated Voice Assistant, such as Amazon Alexa, to access news and traffic information, get sport results, book a trip and much more... with feedback on your TV set
The product includes Wi-Fi 6 technology to offer the best wireless connection with latest generation gateways including for 4K video streams.
After being the first manufacturer to integrate 4K technology, Sagemcom demonstrate with the Video Soundbox its ability to offer the latest technological breakthroughs to the telecom operators, enabling them to create a value proposition based on video service.
“The Video Soundbox allows to combine all services expected today by consumers in an all-in-one compact product, thanks to latest video, sound and voice services innovations developed with best-in-class partners. We are proud to launch the Video Soundbox, with first deployments this summer.”, said Olivier Taravel, Senior Executive Vice President, Audio Video Solutions Business Unit, Sagemcom.
About Sagemcom
Sagemcom is a French industrial group, world leader in high added-value communicating terminals and solutions for the broadband, audio video solutions and energy markets. Sagemcom designs, manufactures and supplies more than 40 million terminals around the world every year, using its own factories and industrial partners on all continents. The headcount of 5,500 employees works in more than 50 countries. Sagemcom has been profitable since its creation in 2008 and 31% of its capital belongs to its employees. In LBO since its 2008 carve-out with Safran, the Group entered its fourth LBO in 2019, with Charterhouse as major shareholder. The Group, which achieved a turnover of 2.1 billion euros in 2020, is led by a stable management team, the majority of whom have been at the helm of Sagemcom since 2008.
www.sagemcom.com // https://www.linkedin.com/company/sagemcom // https://www.instagram.com/sagemcom_inside // https://twitter.com/Sagemcom
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005017/en/
Contact information
Media
Sylvaine COULEUR
presse@sagemcom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom